SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo therapy for head and neck cancer hits early snag
Disease control TerminatedThis phase II trial tested two drug combinations—ibrutinib plus nivolumab or ibrutinib plus cetuximab—in patients with recurrent or metastatic head and neck squamous cell carcinoma. The goal was to see if these combinations could shrink tumors or slow disease progression. However…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Personalized cell therapy shows promise but trial ends early
Disease control TerminatedThis study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Immunotherapy combo tested for tough head and neck cancers
Disease control TerminatedThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation is safe for people with stage IV head and neck cancer. Only 3 patients were enrolled before the study was stopped. The main goal was to find the highest safe do…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New cancer drug shows early promise, but trial cut short
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo aims to stop head and neck cancer relapse in High-Risk patients
Disease control TerminatedThis study tested whether adding the drug xevinapant to standard radiation therapy could help prevent head and neck cancer from coming back after surgery. It included 166 people with high-risk cancer who could not take the usual chemotherapy drug cisplatin. The trial was stopped …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer drug study halted early
Disease control TerminatedThis study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Shasqi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Head and neck cancer trial halted: did xevinapant fall short?
Disease control TerminatedThis phase 3 study tested whether adding the experimental drug Xevinapant to standard chemoradiotherapy could improve outcomes for people with locally advanced head and neck cancer. The trial planned to enroll 730 participants but was terminated early. The main goal was to see if…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Pfizer's new cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
Cancer combo trial halted early: what went wrong?
Disease control TerminatedThis early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:56 UTC
-
Liver damage study in head and neck cancer abandoned after just 2 patients
Knowledge-focused TerminatedThis study aimed to find out how often liver fibrosis and cirrhosis occur in people with head and neck cancer, since tobacco and alcohol are risk factors for both. Researchers planned to check liver health using exams and imaging. However, the study was stopped early after only 2…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC